- Home
- NBBK vs ARVN Comparison
NBBK vs ARVN Comparison
Compare NBBK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | ARVN |
|---|---|---|
| Founded | 1892 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.0M | 781.0M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NBBK | ARVN |
|---|---|---|
| Price | $22.25 | $10.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $23.50 | $15.35 |
| AVG Volume (30 Days) | 190.7K | ★ 838.7K |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | 25.23 | ★ 58.84 |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $45.15 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.44 | $5.90 |
| 52 Week High | $22.75 | $14.22 |
Technical Indicators
Market Signals| Indicator | NBBK | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 62.29 | 41.41 |
| Support Level | $20.17 | $9.02 |
| Resistance Level | $22.65 | $14.03 |
| Average True Range (ATR) | 0.44 | 0.63 |
| MACD | 0.19 | 0.06 |
| Stochastic Oscillator | 80.32 | 34.36 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.